The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer

被引：0
|
作者：
Poma, A. [1 ]
Pasquini, G. [2 ]
Bruno, R. [3 ]
Ali, G. [3 ]
Proietti, A. [3 ]
Pecora, I. [2 ]
Petrini, L. [2 ]
Vasile, E. [2 ]
Chella, A. [4 ]
Fontanini, G. [1 ]
机构：
[1] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy
[3] Univ Hosp Pisa, Anat Pathol Unit, Pisa, Italy
[4] Azienda Osped Univ Pisana, Pneumo Oncol, Pisa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
lung cancer; PD-L1; immunotherapy;
D O I：
10.1016/j.jtho.2019.08.969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-66
引用
收藏
页码：S466 / S467
页数：2
相关论文
共 50 条
  • [31] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
    Qu, Jingjing
    Mei, Quanhui
    Liu, Li
    Cheng, Tianli
    Wang, Peng
    Chen, Lijun
    Zhou, Jianying
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [32] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [33] PD-L1 Expression in Uncommon EGFR-Mutant Non-Small Cell Lung Cancer and Its Response to Immunotherapy
    Chen, K.
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S747 - S747
  • [34] Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer
    Sheffield, Brandon S.
    Fulton, Regan
    Kalloger, Steve E.
    Milne, Katy
    Geller, Georgia
    Jones, Martin
    Jacquemont, Celine
    Zachara, Susanna
    Zhao, Eric
    Pleasance, Erin
    Laskin, Janessa
    Jones, Steven J. M.
    Marra, Marco A.
    Yip, Stephen
    Nelson, Brad H.
    Gown, Allen M.
    Ho, Cheryl
    Ionescu, Diana N.
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2016, 64 (10) : 587 - 600
  • [35] Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer
    Demircan, Volkan
    Acar, Elif
    Senturk, Ertuorul
    Guzel, Cagar
    Eroglu Arkoc, Nazan
    Akyurek, Nalan
    Ozturk, Furkan
    Dincbas, Fazilet
    Akmansu, Muge
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2022, 37 (03): : 227 - 238
  • [36] Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab
    Talb, Jamila
    Kamga, Paul Takam
    Mayenga, Marie
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Dumoulin, Jennifer
    Ouaknine, Julia
    Giraud, Violaine
    Dujon, Cecile
    Azarian, Reza
    Glaser, Claire
    Emile, Jean-Francois
    Leprieur, Etienne Giroux
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2791 - 2799
  • [37] Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
    Meyers, D. E.
    Bryan, P. M.
    Banerji, S.
    Morris, D. G.
    CURRENT ONCOLOGY, 2018, 25 (04) : E324 - E334
  • [38] Interobserver Variability Study of PD-L1 Immunostaining in Non-Small Cell Lung Cancer
    Choi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S998 - S999
  • [39] PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
    Kim, Hyojin
    Chung, Jin-Haeng
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2019, 53 (04) : 199 - 206
  • [40] Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
    Imyanitov, Evgeny N.
    Ivantsov, Alexandr O.
    Tsimafeyeu, Ilya, V
    FRONTIERS IN ONCOLOGY, 2020, 10
12345